| |
Prevention & Management
of
Venous
Thromboembolism
Webcast CME Disclosure
Please read this notice and click the acknowledgement
at the bottom of the page to continue.
Intended Audience:
The educational activity is designed for physicians likely to encounter
patients at risk for VTE, among them: primary care physicians, hospitalist
physicians, critical care specialists/intensivists, orthopedic surgeons,
general surgeons, hematologists, pulmonologists, thrombosis medicine
anticoagulation specialists, hospital-focused internists, surgical oncologists,
and emergency medicine specialists.
Registration:
Enrollment for this WebCAST is complimentary, and clinicians are invited
to participate in this CME-certified WebCAST and/or share this invitation
with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support:
Supported
by an
independent educational grant
from Eisai, Inc.
Designation of Credit:
This activity has been planned and implemented in accordance with the
Essentials and Standards of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the University
of Massachusetts Medical School (UMMS). The UMMS is accredited by ACCME
to provide continuing medical education for physicians.
The UMMS designates this continuing medical education activity for up
to 3 credit hours in Category 1 toward the Physicians Recognition Award
of the American Medical Association. Each physician should claim only
those hours of credit that he/she actually spent in the educational activity.
Statement of Disclosure:
In accordance with the Standards of the Accreditation Council for Continuing
Medical Education (ACCME) and the guidelines of the Association of American
Medical Colleges (AAMC), it is the policy of the University of Massachusetts
Medical School to disclose whatever interest or affiliation a speaker
might have with any commercial organization whose products or services
are related to the subject matter being presented.
Faculty Disclosures:
Samuel Z. Goldhaber, MD
Grant/Research Support: sanofi-aventis, Astra-Zeneca, GSK, Eisai, Mitsubishi
Consultant: sanofi-aventis, Bayer, BMS, Boehringer-Ingelheim
Russell Hull, MBBS, MSc
Grant/Research Support: sanofi-aventis, Bayer
Consultant: sanofi-aventis, Bayer, Wyeth, GSK
Craig M. Kessler, MD
Grant/Research Support: sanofi-aventis, Pfizer, GSK
Consultant: sanofi-aventis, GSK
Speaker's Bureau: sanofi-aventis, GSK
Program Faculty:
Samuel Z. Goldhaber, MD
Program Chairman and Series Medical Director
Professor of Medicine, Cardiovascular Division
Harvard Medical School
Director, Venous Thramboembolism
Research Group
Director, Anticoagulation Service
Brigham and Women's Hospital
Boston, MA
Russell Hull, MBBS, MSc
Professor of Medicine
Director, Thrombosis Research Unit
University of Calgary
Calgary, Alberta Canada
Craig M. Kessler, MD
Professor of Medicine and Pathology
Georgetown University Medical Center
Chief of the Division of Hematology-Oncology
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC
Educational Objectives:
- Clinicians will learn how to apply current guidelines
issued by national professional organizations and
colleges, such as the ACCP, mandating risk-directed
prophylaxis against DVT in at risk patients with medical
and surgical conditions.
- Clinicians will learn to risk stratify medical
and surgical
patients, assess their liklihood for incurring DVT, and be
aware of prophylaxis measures that can reduce the incidence
of DVT in the patient populations.
- Clinicians will learn to assess and
manage special needs
of cancer patients at risk for DVT, with a focus on protecting
against recurrent DVT.
- Clinicians will learn to risk stratify patients
undergoing
general and orthopedic surgery, and implement ACCP-mandated
pharmacologic and non-pharmacologic measures aimed at DVT
prophylaxis.
- Clinicians will learn how to apply landmark clinical
trials focusing on DVT prevention in medical and surgical
patients to their clinical practice.
- Clinicians will learn how to evaluate,
select among, and
appropriately use the range of pharmacologic options available
for DVT prophylaxis, including warfarin, unfractionated heparin,
and LMWHs.
Disclaimer:
Copyright © 2006 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission
is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of
experts, investigators, educators, and clinicians whose activities for,
while independent, are commercially supported by the sponsor noted at
the start of each activity.
Content on this webcast is not meant to be, nor substitute for national
guidelines or recommendations generated by professional, academic societies,
colleges, or associations.
Content on this webcast is intended for educational value only. Its contents,
analyses, and any recommendation made herein are intended to make scientific
information and opinion available to health professionals, to stimulate
thought, and further investigation. This webcast is not designed nor
is any aspect of the contents here intended to provide advice regarding
medical diagnosis or treatment for any individual case. Any decisions
regarding diagnosis and/or management of any individual patient or group
of patients should be made on individual basis after having consulted
appropriate sources, whether they be appropriate consultants and/or guidelines
and recommendations issued by national organizations, professional societies,
governmental health organizations, or similar bodies. This webcast is
not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture,
LLC, program supporters or accreditors, but reflect the opinions and
analyses of the experts who have authored the material. Mention of products
or services does not constitute endorsement. Clinical, legal, financial,
and other comments are offered for general guidance only; and professional
counsel should be sought for all specific situations.
| |
YES, I have read the CME information statement |
Copyright (c) 2007 All rights reserved
|
|